Search

anastrozole 1mg tablet (Arimidex)

Early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen

Exemestane 25mg tablets (Aromasin®)

Postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2 - 3 years of initial adjuvant tamoxifen therapy

Letrozole (Femara®)

Invasive early breast cancer in postmenopausal women who have already received standard tamoxifen therapy.

triptorelin acetate (Decapeptyl)

Triptorelin (Decapeptyl SR 3 mg), a gonadotropin-releasing-hormone (GnRH) agonist, is indicated as adjuvant treatment, in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.

leuprorelin acetate (Prostap DCS)

As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy.

Anastrozole (Arimidex®)

Postmenopausal women with oestrogen receptor positive early invasive breast cancer

Fulvestrant (Faslodex®)

Metastatic breast cancer

Anastrozole 1mg tablets (Arimidex®)

Adjuvant treatment of postmenopausal women with oestrogen receptor- positive early invasive breast cancer

Search results